Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hartmann

Showing results (341-350 of 472) with videos related to

Pageof 48
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 2013
Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998)R B Keus, R A Nout, J-Y Blay, et al.
The Lancet. Oncology|April 17, 2012
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trialRalf-Dieter Hofheinz, Frederik Wenz, Stefan Post, et al.
Cancer|April 17, 2014
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinibHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 5, 2003
The LPS receptor (CD14) links innate immunity with Alzheimer's diseaseK Fassbender, S Walter, S Kühl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2007
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015C-H Köhne, J De Greve, J T Hartmann, et al.
The Lancet. Oncology|March 13, 2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialIan Judson, Jaap Verweij, Hans Gelderblom, et al.
Scientific Reports|July 24, 2024
An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animalsAnna Offersgaard, Carlos R Duarte Hernandez, Yuyong Zhou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2021
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)<sup>☆</sup>P G Casali, A Le Cesne, A P Velasco, et al.
JAMA|March 29, 2012
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trialHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Annals of Clinical Biochemistry|April 4, 2009
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's diseaseN A Verwey, W M van der Flier, K Blennow, et al.
Pageof 48

Showing results (341-350 of 472) with videos related to

Sort By:
Pageof 48
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 2013
Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998)R B Keus, R A Nout, J-Y Blay, et al.
The Lancet. Oncology|April 17, 2012
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trialRalf-Dieter Hofheinz, Frederik Wenz, Stefan Post, et al.
Cancer|April 17, 2014
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinibHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 5, 2003
The LPS receptor (CD14) links innate immunity with Alzheimer's diseaseK Fassbender, S Walter, S Kühl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2007
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015C-H Köhne, J De Greve, J T Hartmann, et al.
The Lancet. Oncology|March 13, 2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialIan Judson, Jaap Verweij, Hans Gelderblom, et al.
Scientific Reports|July 24, 2024
An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animalsAnna Offersgaard, Carlos R Duarte Hernandez, Yuyong Zhou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2021
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)<sup>☆</sup>P G Casali, A Le Cesne, A P Velasco, et al.
JAMA|March 29, 2012
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trialHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Annals of Clinical Biochemistry|April 4, 2009
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's diseaseN A Verwey, W M van der Flier, K Blennow, et al.
Pageof 48